- Home
- TBN vs BDX Comparison
TBN vs BDX Comparison
Compare TBN & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBN
- BDX
- Stock Information
- Founded
- TBN 2009
- BDX 1897
- Country
- TBN Australia
- BDX United States
- Employees
- TBN N/A
- BDX N/A
- Industry
- TBN
- BDX Medical/Dental Instruments
- Sector
- TBN
- BDX Health Care
- Exchange
- TBN NYSE
- BDX Nasdaq
- Market Cap
- TBN 43.4B
- BDX 49.0B
- IPO Year
- TBN 2024
- BDX 1962
- Fundamental
- Price
- TBN $19.82
- BDX $181.01
- Analyst Decision
- TBN Buy
- BDX Buy
- Analyst Count
- TBN 3
- BDX 9
- Target Price
- TBN $35.67
- BDX $231.50
- AVG Volume (30 Days)
- TBN 28.1K
- BDX 2.9M
- Earning Date
- TBN 09-19-2025
- BDX 08-07-2025
- Dividend Yield
- TBN N/A
- BDX 2.28%
- EPS Growth
- TBN N/A
- BDX 14.07
- EPS
- TBN N/A
- BDX 5.16
- Revenue
- TBN N/A
- BDX $20,867,000,000.00
- Revenue This Year
- TBN N/A
- BDX $9.24
- Revenue Next Year
- TBN N/A
- BDX $4.85
- P/E Ratio
- TBN N/A
- BDX $35.33
- Revenue Growth
- TBN N/A
- BDX 5.84
- 52 Week Low
- TBN $15.75
- BDX $163.33
- 52 Week High
- TBN $34.50
- BDX $251.99
- Technical
- Relative Strength Index (RSI)
- TBN N/A
- BDX 58.30
- Support Level
- TBN N/A
- BDX $175.31
- Resistance Level
- TBN N/A
- BDX $185.92
- Average True Range (ATR)
- TBN 0.00
- BDX 3.78
- MACD
- TBN 0.00
- BDX 0.62
- Stochastic Oscillator
- TBN 0.00
- BDX 73.63
About TBN TAMBORAN RESOURCES CORPORATION
Tamboran Resources Corp is a gas company focused on supporting the Net Zero CO2 energy transition in Australia and Asia-Pacific through developing low CO2 unconventional gas resources in the Australian Northern Territory.
About BDX Becton Dickinson and Company
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (27% of 2024 revenue) and BD Interventional (24%) account for the remainder. International revenue accounts for 43% of the company's business.